Athenex (ATNX) to Release Earnings on Tuesday

Athenex (NASDAQ:ATNX) will announce its earnings results before the market opens on Tuesday, August 14th.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings results on Monday, May 14th. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.05). Athenex had a negative return on equity of 75.45% and a negative net margin of 136.72%. The company had revenue of $37.84 million during the quarter. On average, analysts expect Athenex to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ ATNX opened at $18.40 on Monday. Athenex has a 52 week low of $13.28 and a 52 week high of $20.90.

ATNX has been the topic of a number of recent analyst reports. BidaskClub cut Athenex from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 19th. ValuEngine upgraded Athenex from a “hold” rating to a “buy” rating in a research report on Friday, June 15th. Finally, Zacks Investment Research upgraded Athenex from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research report on Friday, June 8th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Athenex has an average rating of “Buy” and a consensus target price of $26.71.

In other Athenex news, Director Sheldon Trainor-Degirolamo sold 121,688 shares of Athenex stock in a transaction dated Wednesday, May 23rd. The stock was sold at an average price of $17.01, for a total value of $2,069,912.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Song-Yi Zhang sold 70,584 shares of Athenex stock in a transaction dated Tuesday, May 29th. The shares were sold at an average price of $16.07, for a total value of $1,134,284.88. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at approximately $64,280. The disclosure for this sale can be found here. In the last quarter, insiders sold 301,392 shares of company stock worth $5,041,671. Company insiders own 29.50% of the company’s stock.

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Featured Story: Understanding Analyst Ratings

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply